Voormolen, N., Noordzij, M., Grootendorst, D.C., Beetz, I., Sijpkens, Y.W., van Manen, J.G., et al. (2007) High Plasma Phosphate as a Risk Factor for Decline in Renal Function and Mortality in Pre-Dialysis Patients. Nephrology Dialysis Transplantation, 22, 2909-2916.
http://dx.doi.org/10.1093/ndt/gfm286

has been cited by the following article:

• TITLE: Effect of Sevelamer Hydrochloride on the Serum Calcitriol Concentration in Hemodialysis Patients

  AUTHORS: Kazumichi Matsushita, Keitaro Sato, Kohei Unagami, Kosaku Nitta, Kiichiro Tago

  KEYWORDS: Hemodialysis, Calcitriol, Sevelamer Hydrochrolide, Lanthanum Carbonate, Bioavailability

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.5 No.20, November 25, 2014

  ABSTRACT: Back ground: There are no published clinical data in hemodialysis (HD) patients with mineral bone disorder (CKD-MBD) regarding the effect of sevelamer hydrochloride on the absorption of the oral calcitriol. Objectives: The aim of the present study was to determine the association of the sevelamer hydrochloride and serum 1-25(OH)2D concentration during oral calcitriol therapy. Methods: This was a before-and-after study in HD patients. Forty-six patients co-administered with phosphate-binder and calcitriol for CKD-MBD therapy took lanthanum carbonate (LC) and sevelamer hydrochloride (SH) for 4 weeks, respectively with calcitriol. The serum 1-25(OH)2D concentration was assessed after each period. Results: Serum 1-25(OH)2D concentration was significantly reduced with co-administration of SH compared to LH (mean, calcitriol with LC→SH: 19.9 pg/ml → 14.2 pg/ml, p 2D concentrations after oral calcitriol administration compared to LH in HD patients. When we use SH as a phosphate binder with calcitriol for HD patients with CKD-MBD, we should consider the inhibitory effect of SH on oral calcitriol absorption.